tadalafil

(redirected from Adcirca)
Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for tadalafil

virility drug (trade name Cialis) used to treat erectile dysfunction in men

References in periodicals archive ?
NASDAQ: UTHR) pediatric exclusivity for Adcirca (tadalafil) tablets through May 21, 2018, based on study results submitted by Eli Lilly and Company (Lilly) in response to a written request by the FDA to investigate the use of tadalafil in pediatric patients with Duchenne muscular dystrophy, the company said.
United Therapeutics markets and sells Adcirca for treatment of pulmonary arterial hypertension (PAH) in the US under a license agreement with Lilly.
A US patent for Adcirca will expire November 21, 2017, and FDA's decision provides an additional six months of regulatory exclusivity running from this date, providing an additional six months before FDA can approve a generic version of Adcirca.
The increase in sales and marketing expenses corresponds primarily to expenses incurred related to marketing our new products, Tyvaso and Adcirca.
Silver Spring MD), which markets Adcirca in the United States.
Our increased stock price also highlights our mature pipeline, which has the potential for further growth through continued market penetration by Remodulin, our recent launch of Adcirca, the only once-daily PDE-5 inhibitor for PAH, and the expected launch of Tyvaso, our now FDA-approved inhaled prostacyclin analogue.
The various drugs used to treat PAH are: Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil), and Veletri (epoprostenol).
United Therapeutics Corporation and Lung Rx, LLC announced today the launch of a nationwide support program for patients who are currently prescribed a United Therapeutics therapy, which includes Remodulin (treprostinil) Injection, Adcirca (tadalafil) tablets or Tyvaso (treprostinil) Inhalation Solution.
The Adcirca Reimbursement Hotline, 877-948-9136, will also continue to be a resource for patients and health care providers to provide insurance benefits investigation, reimbursement assistance and other support.